期刊
ALLERGY
卷 76, 期 5, 页码 1367-1384出版社
WILEY
DOI: 10.1111/all.14666
关键词
accidental exposure; anaphylaxis; burden; health-related quality of life; peanut allergy
资金
- Aimmune Therapeutics
Peanut allergy (PA) affects around 2% of the general population in Western countries, leading to significant burden of self-management for patients and their families/caregivers. PA is associated with higher rates of accidental exposure, severe reactions, and potential fatal anaphylaxis compared to other food allergies, resulting in considerable healthcare utilization and economic costs.
Peanut allergy (PA) currently affects approximately 2% of the general population of Western nations and may be increasing in prevalence. Patients with PA and their families/caregivers bear a considerable burden of self-management to avoid accidental peanut exposure and to administer emergency medication (adrenaline) if needed. Compared with other food allergies, PA is associated with higher rates of accidental exposure, severe reactions and potentially fatal anaphylaxis. Approximately 7%-14% of patients with PA experience accidental peanut exposure annually, and one-third to one-half may experience anaphylaxis, although fatalities are rare. These risks impose considerably high healthcare utilization and economic costs for patients with PA and restrictions on daily activities. Measures to accommodate patients with PA are often inadequate, with inconsistent standards for food labelling and inadequate safety policies in public establishments such as restaurants and schools. Children with PA are often bullied, resulting in sadness, humiliation and anxiety. These factors cumulatively contribute to significantly reduced health-related quality of life for patients with PA and families/caregivers. Such factors also provide essential context for risk/benefit assessments of new PA therapies. This narrative review comprehensively assessed the various factors comprising the burden of PA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据